Overview

A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the long-term efficacy and safety of two dosages of bicifadine SR (600 mg/day and 1200 mg/day) for up to 52 weeks in reducing chronic peripheral neuropathy pain due to diabetes in adult outpatients.
Phase:
Phase 2
Details
Lead Sponsor:
XTL Biopharmaceuticals